Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 71.79x is 23% below its estimated 1-year average of 93.84x, near the low end of its estimated 1-year range (71.79x–121.94x).
As of 2026-10-06T19:53:41.406Z.
Calculation as of: 2026-10-06T19:53:41.406Z.
Quote observation: 2026-10-06T19:50:34.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bd9bff75293b0061b415f76424971e71050022ba1ca13a61eeb09eda3fdb1614
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
71.79x
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.36x
median of 549 covered companies
CURRENT VS SECTOR MEDIAN
+1546.56%
vs the sector median at left
Rapport Therapeutics, Inc. Common Stock
Market Cap
$1.49B
EV/Sales Ratio
71.79x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.48B
EV/Sales Ratio
1.46x
TTM Avg
1.67x
3Y Avg
1.40x
5Y Avg
1.32x
Market Cap
$1.50B
EV/Sales Ratio
14.21x
TTM Avg
10.18x
3Y Avg
7.41x
5Y Avg
6.19x
Market Cap
$1.46B
EV/Sales Ratio
66.03x
TTM Avg
138.10x
3Y Avg
89.44x
5Y Avg
89.44x
Market Cap
$1.53B
EV/Sales Ratio
7.08x
TTM Avg
12.64x
3Y Avg
77.84x
5Y Avg
74.59x
Market Cap
$1.45B
EV/Sales Ratio
0.70x
TTM Avg
0.73x
3Y Avg
0.58x
5Y Avg
0.61x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $1.49B | 71.79x | N/A | N/A | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 1.46x | 1.67x | 1.40x | 1.32x |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 14.21x | 10.18x | 7.41x | 6.19x |
| Nutex Health, Inc. (NUTX)vs › | $1.50B | 1.94x | 1.37x | 1.46x | 3.65x |
| GH Research PLC (GHRS)vs › | $1.47B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 66.03x | 138.10x | 89.44x | 89.44x |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.53B | 7.08x | 12.64x | 77.84x | 74.59x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 0.70x | 0.73x | 0.58x | 0.61x |
| Certara, Inc. (CERT)vs › | $1.44B | 3.80x | 3.18x | 5.10x | 7.42x |
| Innoviva, Inc. (INVA)vs › | $1.54B | 2.79x | 3.82x | 4.31x | 4.24x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2026-10-05 | 73.73x |
| 2026-10-02 | 73.69x |
| 2026-10-01 | 75.25x |
| 2026-09-30 | 77.08x |
| 2026-09-29 | 75.70x |
| 2026-09-28 | 76.70x |
| 2026-09-25 | 77.82x |
| 2026-09-24 | 77.63x |
| 2026-09-23 | 78.34x |
| 2026-09-22 | 95.76x |
| 2026-09-21 | 91.46x |
| 2026-09-18 | 93.34x |
| 2026-09-17 | 96.90x |
| 2026-09-16 | 95.57x |
| 2026-09-15 | 98.63x |
| 2026-09-14 | 101.77x |
| 2026-09-11 | 100.86x |
| 2026-09-10 | 100.48x |
| 2026-09-09 | 101.50x |
| 2026-09-08 | 106.73x |
| 2026-09-04 | 105.97x |
| 2026-09-03 | 110.43x |
| 2026-09-02 | 112.90x |
| 2026-09-01 | 112.59x |
| 2026-08-31 | 112.85x |
| 2026-08-28 | 113.09x |
| 2026-08-27 | 117.98x |
| 2026-08-26 | 121.94x |
| 2026-08-25 | 118.78x |
| 2026-08-24 | 114.42x |
| 2026-08-21 | 111.83x |
| 2026-08-20 | 110.90x |
| 2026-08-19 | 113.80x |
| 2026-08-18 | 113.66x |
| 2026-08-17 | 112.26x |
| 2026-08-14 | 109.88x |
| 2026-08-13 | 109.74x |
| 2026-08-12 | 110.62x |
| 2026-08-11 | 113.21x |
| 2026-08-10 | 108.84x |
| 2026-08-07 | 105.30x |
| 2026-08-06 | 107.34x |
| 2026-08-05 | 96.87x |
| 2026-08-04 | 96.31x |
| 2026-08-03 | 92.98x |
| 2026-07-31 | 93.43x |
| 2026-07-30 | 97.68x |
| 2026-07-29 | 93.33x |
| 2026-07-28 | 95.74x |
| 2026-07-27 | 96.14x |
| 2026-07-24 | 92.72x |
| 2026-07-23 | 94.37x |
| 2026-07-22 | 94.25x |
| 2026-07-21 | 97.16x |
| 2026-07-20 | 91.61x |
| 2026-07-17 | 97.30x |
| 2026-07-16 | 91.42x |
| 2026-07-15 | 90.95x |
| 2026-07-14 | 94.56x |
| 2026-07-13 | 92.50x |
| 2026-07-10 | 95.24x |
| 2026-07-09 | 95.95x |
| 2026-07-08 | 95.81x |
| 2026-07-07 | 90.45x |
| 2026-07-06 | 87.73x |
| 2026-07-02 | 88.68x |
| 2026-07-01 | 89.67x |
| 2026-06-30 | 95.05x |
| 2026-06-29 | 92.03x |
| 2026-06-26 | 91.25x |
| 2026-06-25 | 88.54x |
| 2026-06-24 | 91.11x |
| 2026-06-23 | 88.47x |
| 2026-06-22 | 86.84x |
| 2026-06-18 | 84.83x |
| 2026-06-17 | 83.72x |
| 2026-06-16 | 87.54x |
| 2026-06-15 | 87.00x |
| 2026-06-12 | 87.33x |
| 2026-06-11 | 79.80x |
| 2026-06-10 | 79.80x |
| 2026-06-09 | 81.29x |
| 2026-06-08 | 83.27x |
| 2026-06-05 | 81.90x |
| 2026-06-04 | 85.18x |
| 2026-06-03 | 84.03x |
| 2026-06-02 | 79.07x |
| 2026-06-01 | 84.28x |
| 2026-05-29 | 89.93x |
| 2026-05-28 | 89.91x |
| 2026-05-27 | 89.95x |
| 2026-05-26 | 90.43x |
| 2026-05-22 | 85.73x |
| 2026-05-21 | 83.32x |
| 2026-05-20 | 81.00x |
| 2026-05-19 | 77.81x |
| 2026-05-18 | 79.73x |
| 2026-05-15 | 84.19x |
| 2026-05-14 | 86.27x |
| 2026-05-13 | 86.58x |
| 2026-05-12 | 84.59x |
| 2026-05-11 | 87.40x |
| 2026-05-08 | 86.48x |
